T-Pharmacytes for the Eradication of Latent HIV Reservoirs

Technology #15960

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
FIG. 1 T-pharmacytes induce expression of latent HIV. Clear induction was observed of Gag expression in C04+ target cells co-cultured with bulk C08+ cells that were conjugated to IL-15SA loaded ICMVs, but not in those co-cultured with C08+ cells conjugated to empty ICMVs (neg control).FIG. 2 shows a schematic depicting a non-limiting example of a method of the invention for systemic targeting of latent HIV reservoirs
Categories
Inventors
Professor Darrell Irvine
Department of Biological Engineering, MIT
External Link (irvine-lab.mit.edu)
Bruce Walker
Massachusetts General Hospital
Richard Jones
Koch Institute for Integrative Cancer Research, MIT
Managed By
Jon Gilbert
MIT Technology Licensing Officer
Patent Protection

Methods and compositions for localized delivery of agents to virally infected cells and tissues

US Patent Pending 2014-0170221

Applications

This invention uses latency activation combined with a potent immune response to eliminate viral reservoirs for treatment of infections such as human immunodeficiency virus (HIV).

Problem Addressed

Infected resting memory CD4+ T-cells are thought to re-seed systemic infection after cessation of antiviral therapy making it difficult to cure viral infections like HIV. Cells in this resting state do not produce virus and thus neither die by viral cytopathic mechanisms nor are effectively targeted by the immune system. Latency-reversing drugs (LRDs) that induce HIV expression from and thus expose viral reservoirs have decreased cells harboring inducible provirus, but cannot successfully eradicate infection. Current strategies have failed due to the incomplete ability of LRDs to effectively reach reservoirs of virus in tissues and the insufficiency of virus reactivation or endogenous immune responses to eliminate infected cells upon transient latency reversal. This invention addresses these issues for improved treatment of latent viral infections.

Technology

Drug-loaded nanoparticles (NPs) are coupled to the surface of CD8+ T-cells, creating drug-delivery effector cells named T-Pharmacytes by the inventors. These cells, with their intrinsic tissue homing patterns, will deliver LRDs into the tissue sites where infected cells reside, and promote sustained, high dosing levels in these tissues. This invention uses a superagonist form of the cytokine interleukin-15, IL-15SA, a LDR that is more potent and less toxic than the earlier discovered interleukin-2 (IL-2). IL-15SA released from pharmacytes will stimulate viral transcription in latently-infected CD4+ T-cells and effector functions of the carrier cytotoxic T-Iymphocyte (CTL); HIV antigen expression by the infected cell will trigger recognition of viral peptides by the pharmacyte CTL, leading to killing of the infected target cell. Antiretrovirals will be co-administered to block residual progeny virus. Retention of the NP-CTLs at sites of antigen recognition will provide a positive feedback loop leading to additional drug release in reservoir sites where HIV is detected.

Advantages

  • Efficiently eliminates viral reservoirs
  • Continuously targets tissues with infected cells due to positive feedback loop